ArticleLeukemia2020

Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).

Andreas Neubauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.